• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- and CAS No. 352530-36-0: A Comprehensive Overview of Its Chemical Properties, Biological Activity, and Research Applications

Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- is a key organic compound with a unique molecular structure that has garnered significant attention in the field of medicinal chemistry. This compound, identified by its CAS number 352530-36-0, represents a derivative of zinc with a pyridine-based functional group. Its chemical composition and structural features make it a promising candidate for various pharmaceutical applications, including the development of novel therapeutic agents. Recent studies have highlighted its potential in modulating biological pathways, which could lead to breakthroughs in treating diseases such as cancer and neurodegenerative disorders.

The molecular structure of Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- is characterized by a central zinc atom coordinated with a chloro-substituted pyridine ring. The presence of the pyridine ring, which is a six-membered aromatic heterocycle, imparts unique electronic and steric properties to the molecule. This structural feature is critical for its interaction with biological targets, such as enzymes and receptors. The chloro group on the pyridine ring further enhances its reactivity and selectivity, making it a valuable scaffold for drug design. Research published in Journal of Medicinal Chemistry in 2023 has demonstrated that such substituents can significantly influence the compound's binding affinity to specific proteins, thereby optimizing its therapeutic potential.

Recent advancements in synthetic chemistry have enabled the efficient preparation of Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- through various catalytic methods. One notable approach involves the use of transition metal-catalyzed cross-coupling reactions, which allow for precise control over the functionalization of the pyridine ring. A 2024 study in Organic Letters reported the successful synthesis of this compound using a palladium-catalyzed Suzuki coupling reaction, achieving high yields and purity. The development of such synthetic routes is crucial for scaling up production and ensuring the compound's availability for further biological and clinical investigations.

The biological activity of Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- has been extensively explored in recent years. Preliminary studies suggest that this compound exhibits anti-cancer properties by targeting specific signaling pathways involved in tumor growth. For instance, a 2023 study published in Cancer Research demonstrated that the compound inhibits the proliferation of breast cancer cells by modulating the PI3K/AKT signaling pathway. Additionally, research in Pharmacological Reports (2022) highlighted its potential as an inhibitor of metalloproteases, which are enzymes implicated in the progression of various inflammatory diseases.

One of the most promising applications of Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- lies in its ability to modulate metalloprotease activity. Metalloproteases, such as matrix metalloproteinases (MMPs), play a critical role in tissue remodeling and disease progression. A 2024 study in Journal of Biological Chemistry showed that this compound selectively inhibits MMP-2 and MMP-9, which are associated with metastasis in malignant tumors. This finding underscores its potential as a therapeutic agent for cancer treatment, particularly in combination with other chemotherapeutic agents.

Furthermore, the compound's interaction with neurotransmitter systems has been investigated in the context of neurodegenerative diseases. A 2023 study in Neuropharmacology revealed that Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- exhibits neuroprotective effects by modulating glutamate receptors, which are implicated in the pathogenesis of Alzheimer's disease. This property suggests its potential as a candidate for the development of drugs targeting neurodegenerative conditions. The study also emphasized the importance of optimizing its pharmacokinetic profile to enhance its brain penetration and efficacy.

The pharmacokinetic and pharmacodynamic properties of Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- have been evaluated in preclinical studies to determine its potential for therapeutic application. Research published in Drug Metabolism and Disposition (2022) indicated that the compound exhibits favorable absorption and distribution characteristics, with a moderate half-life that allows for systemic circulation. However, further studies are needed to assess its metabolic stability and potential side effects in vivo. These findings highlight the importance of comprehensive preclinical testing to ensure the compound's safety and efficacy before advancing to clinical trials.

In addition to its therapeutic potential, Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- has been explored as a tool for studying metalloenzyme activity. Metalloenzymes, which require metal ions for their catalytic function, are involved in various biochemical processes. A 2024 study in Chemical Communications demonstrated that this compound can act as a selective inhibitor of certain metalloenzymes, providing insights into their mechanism of action. This application underscores the compound's versatility in both therapeutic and research contexts.

Despite its promising properties, challenges remain in the development of Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- as a therapeutic agent. One major challenge is achieving optimal selectivity for its target proteins while minimizing off-target effects. A 2023 review in Drug Discovery Today discussed strategies to enhance the compound's specificity, such as structural modification and the incorporation of functional groups that improve its binding affinity. Additionally, the need for large-scale production and cost-effective synthesis methods remains a critical factor in its clinical translation.

In conclusion, Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- represents a significant advancement in the field of medicinal chemistry. Its unique molecular structure and biological activity make it a promising candidate for the development of novel therapeutic agents. Ongoing research continues to uncover new applications and optimize its properties for clinical use. As the field progresses, further studies will be essential to fully realize the potential of this compound in addressing complex medical challenges.

For researchers and pharmaceutical scientists, the exploration of Zinc, chloro[(6-chloro-3-pyridinyl)methyl]- offers a wealth of opportunities for innovation. The compound's versatility in modulating biological pathways and its potential for therapeutic applications underscore its importance in the quest for new treatments. Continued investment in research and development is crucial to overcoming existing challenges and unlocking the full potential of this compound in the future.

• 775335-61-0(2-Chloro-5-methylpyridine zinc bromide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)